课题基金 / 基金详情

CONCURRENT RADIATION AND GERCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS

CONCURRENT RADIATION AND GERCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS
同步放疗和吉西他滨治疗不可切除的头颈部肿瘤
批准号：
5216256
负责人：
Avraham Eisbruch
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5216256
关键词：
antineoplastics clinical research clinical trial phase I combination cancer therapy drug metabolism head /neck neoplasm human subject neoplasm /cancer radiation therapy

项目摘要

项目成果

Avraham Eisbruch的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项I期研究寻求最大耐受剂量
英文摘要
This is a phase I study seeking the maximally tolerated dose of gemcitabine delivered concurrent with a standard course of radiation for patients with unresectable head and neck tumors. Plasma levels and tumor incorporation of gemcitabine, as well as tumor nucleotide pools will be measured in order to gain a better understanding of the mechanisms by which gemcitabine may enhance radiation antitumoral activity in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INDIVIDUALIZING IMRT TREATMENT IN BRAIN AND HEAD/NECK CA
CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS
QUALITY OF LIFE IN HEAD AND NECK CANCER
CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS
海外基金